

APPENDIX 2 - Estimated savings for 16-17	Likelihood of Achieving Estimate	Gross savings £000's	Investment £000's	Net Savings £000's	Actual Savings £000's	Full Year Effect	Unavoidable Spending Increases	Estimated gross Increase £000's
Primary Care:								
General Prescribing Support input.	High	31	0	31			Price Increases	
Scriptswitch (all practices)	Medium	120	40	60	24.7		Ropinirole (shortage)	TBC
Prescribing Efficiency LES - Non Clinical Med Review	Medium	84	36	48			Spend increases from range of drug price increase (refer to Increases spreadsheet Quarter 1 Primary Care only)	-258.00
Prescribing Efficiency LES - Oxycodone brand change	High	60	13	47				
Prescribing Efficiency LES - Combination inhaler review	High	18.7	20.6	-1.9				
Prescribing Efficiency LES - repeat prescribing system review	Low	42	41.4	0.6				
PST Technicians reviews	High	45	45	0				
Flu vaccine reduced cost	High	55.76	0	55.76				
Patent Expiries	Medium	39.3	0	39.3				
Polypharmacy	Medium			0				
Primary Care Rebates	Medium	6.5	0	6.5		9.5		
Blood glucose meter and Insulin needle swap	High	56.5	0	56.5	19			
Sub total		558.76	196	342.76	43.7	9.5		
Waste Programme	Low							
Sub total		0	0	0	0	0		
Secondary Care - aim £60k								
Rituximab biosimilar	Low	100	0	100			Rifampicin capsules shortage	TBC
Etanercept biosimilar	Medium	240	50	190			Zoledronic acid 5mg contract shortage	TBC
IV fluids - new clinical guidance	High			0			Nabilone shortage and price increase	TBC
Infliximab biosimilar Introduction	High	33.41	0	33.41	13.22			
Patent Expiry	Medium			0				
High Cost Drugs to HBP	High			0	17.55			
pegfilgrastim to Lipegfilgrastim (formulary change)	High	8.26	0	8.26				
Apixaban reduced price	High			0				
Bendamustine reduced price	High	30		30				
Linezolid reduced price	Medium	7.5	0	7.5				
Rituximab ready made bags - reduced price	High	3.74	0	3.74		3.74		
Golimumab outcome rebate	High		0	0	8.85			
HIV Drugs	High		0	0	6.16			
Off Contract Recovery	High		0	0	31			
Adrenaline pen brand change	High	40	0	40				
Oxycodone brand change	High			0				
Secukinemab FOC initiation	High			0	8.24			
Ranibizumab (Lucentis) contract	High	135	0	135	33.9			
Dexamethasone product change	High	7.33	0	7.33		11		
Sub total		605.24	50	555.24	118.92	14.74		
Total		1164	246	898	162.62	24.24		
Non Cash Efficiencies		Length of Stay	Patients Admitted					
Updated 11.08.16								